The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus

• Status: Unknown status
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to validate the hypothesis that the treatment of rosuvastatin could increase the score of Calcification of Coronary artery(CAC) density in coronary artery disease(CAD) patients with diabetes mellitus.CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sir Run Run Shaw Hospital
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

1. Provision of informed consent prior to any study specific procedures

2. Male and female adults aged 18-70 years old

3. CHD patients without stent implantation determined by coronary angiography or coronary CT examination;

4. Combined with type 2 diabetes: HbA1c≥6.5%, FPG≥7.0mmol/L, 2h blood glucose≥11.1mmol/L

5. Patients who confirmed CAC(Agatston score ≥50,measured by 64 row spiral CT6)

Exclusion Criteria:

1. CHD Patients plan to recieve coronary stenting implantation or coronary artery bypass grafting;

2. Patients combined with severe pulmonary, liver and kidney dysfunction

3. Classed as III-IV grade of New York Heart Association functional

4. Pregnancy test was positive，lactation woman and in women of child-bearing potential not using appropriate contraceptive measures.

5. Life expectancy within 24 months or less

6. Patients combined valvular heart disease and cardiomyopathy

7. Patients combined cancer

8. Patients with atrial fibrillation

9. Patients who is allergic to statins

10. Patients with myopathy

11. Patients with active liver disease